(Q37801267)

23 August 2017

title

Prognostic factors in chronic lymphocytic leukemia-what do we need to know? (English)

1 reference

23 August 2017

0 references

1 reference

2

Michael Hallek

1 reference

23 August 2017

Paula Cramer

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

19 October 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

published in

1 reference

23 August 2017

volume

8

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

38-47

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2010.167

23 August 2017

exact match

0 references

cites work

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

31 March 2020

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Sex differences in incidence and outcome of chronic lymphocytic leukemia patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Disease burden of chronic lymphocytic leukaemia within the European Union

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

β2-Microglobulin in Chronic Lymphocytic Leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. A multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Prognostic relevance of a scoring system based on clinical and biological parameters in early chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Genomic aberrations and survival in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Karyotypic evolution in B-cell chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

New prognostic markers in CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Clinical significance of CD38 expression in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Treatment of elderly patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Management of cancer in the older person: a practical approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Aging, frailty, and chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Predicting clinical outcome in CLL: how and why.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

From pathogenesis to treatment of chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Validation of a new prognostic index for patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.167

Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases.

31 March 2020

1 reference

12 December 2020

Prognostic relevance of a scoring system based on clinical and biological parameters in early chronic lymphocytic leukemia

1 reference

12 December 2020

Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases

1 reference

12 December 2020

Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic significance

1 reference

12 December 2020

V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

1 reference

12 December 2020

Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia

1 reference

12 December 2020

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

12 December 2020

Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

Clinical staging of chronic lymphocytic leukemia

1 reference

12 December 2020

11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis

1 reference

12 December 2020

CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.

1 reference

12 December 2020

Clinical significance of sIL2R, sCD23, sICAM-1, IL6 and sCD 14 serum levels in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Immunoglobulin V genes and CD38 expression in CLL

1 reference

12 December 2020

The geriatric cancer patient: equal benefit from equal treatment

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy

1 reference

12 December 2020

Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors

1 reference

12 December 2020

10.1038/NRCLINONC.2010.167

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1022243665

0 references

1 reference